文献速递淋巴瘤

BRUIN CLL-313:Pirtobrutinib对比苯达莫司汀联合利妥昔单抗一线治疗CLL/SLL的III期随机试验

BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
PubMed 文献 · J Clin Oncol · 2025-12-09

BRUIN CLL-313是一项随机、开放标签、全球III期研究,在无del(17p)的初治CLL/SLL患者中比较Pirtobrutinib单药与苯达莫司汀联合利妥昔单抗(BendaR)。Pirtobrutinib耐受性良好,安全性优于BendaR。

要点

  • Pirtobrutinib一线治疗CLL/SLL较BendaR显著改善IRC评估PFS(HR 0.199)。
  • 24个月PFS率Pirtobrutinib组93.4%,BendaR组70.7%。
  • Pirtobrutinib安全性更优,AE相关减量和停药率均低于BendaR。

核心结论

  • 在无del(17p)的初治CLL/SLL患者中,Pirtobrutinib较BendaR显著改善IRC评估的无进展生存期。
  • 总生存期中期分析趋势 favoring Pirtobrutinib,尽管设计允许交叉。
  • Pirtobrutinib耐受性良好,安全性优于BendaR。

研究设计与样本

  • 随机、开放标签、全球III期研究,比较Pirtobrutinib单药与苯达莫司汀联合利妥昔单抗(BendaR)。
  • 纳入既往未治疗、无del(17p)的CLL/SLL患者,按1:1随机分组,按免疫球蛋白重链基因突变状态和Rai分期分层。
  • 共282例患者随机接受Pirtobrutinib(n=141)或BendaR(n=141)。
  • 主要终点为独立评审委员会(IRC)评估的无进展生存期(PFS)。

主要发现

  • 24个月PFS率:Pirtobrutinib组93.4%(95%CI 87.6-96.5),BendaR组70.7%(95%CI 61.5-78.1)。
  • 研究者评估PFS同样 favoring Pirtobrutinib:HR 0.186(95%CI 0.093-0.371)。
  • 总生存期中期分析(中位随访32个月) favoring Pirtobrutinib:HR 0.257(95%CI 0.070-0.934),有效交叉率52.9%。
  • 安全性:Pirtobrutinib组 vs BendaR组,AE相关剂量减少3.6% vs 31.1%,≥3级TEAE 40.0% vs 67.4%,因TEAE停药4.3% vs 15.2%。

关键数值与推荐

  • 24个月PFS率Pirtobrutinib组93.4%(95%CI 87.6-96.5),BendaR组70.7%(95%CI 61.5-78.1)。
  • OS中期分析HR 0.257(95%CI 0.070-0.934),中位随访32个月。
  • AE相关剂量减少率3.6% vs 31.1%,≥3级TEAE发生率40.0% vs 67.4%,因TEAE停药率4.3% vs 15.2%(Pirtobrutinib vs BendaR)。

临床怎么用

  • 对于无del(17p)的初治CLL/SLL患者,Pirtobrutinib单药可作为优于BendaR的一线治疗选择。
  • Pirtobrutinib的安全性特征更有利,AE相关减量和停药率更低,支持其长期使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: BRUIN CLL-313 is a randomized, open-label, global phase III study comparing the efficacy and safety of pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), against bendamustine plus rituximab (BendaR), a common frontline chemoimmunotherapy, in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). METHODS: Patients with previously untreated CLL/SLL without del(17p) were randomly assigned 1:1 to continuous pirtobrutinib monotherapy or BendaR, stratified by immunoglobulin heavy chain gene mutation status and Rai stage. The primary end point was independent review committee (IRC)-assessed progression-free survival (PFS); secondary end points included overall survival (OS), investigator (INV)-assessed PFS, safety, and tolerability. RESULTS: Overall, 282 patients were randomly assigned to receive pirtobrutinib (n = 141) or BendaR (n = 141). IRC-assessed PFS was significantly improved with pirtobrutinib versus BendaR (hazard ratio [HR], 0.199 [95% CI, 0.107 to 0.367]; P < .0001), and the 24-month PFS rate was 93.4% (95% CI, 87.6 to 96.5) and 70.7% (95% CI, 61.5 to 78.1), respectively. INV-assessed PFS similarly favored pirtobrutinib (HR, 0.186 [95% CI, 0.093 to 0.371]). Interim analysis of OS favored pirtobrutinib (median follow-up 32 months; HR, 0.257 [95% CI, 0.070 to 0.934]) despite an effective crossover rate of 52.9%. In patients receiving pirtobrutinib versus BendaR: adverse event (AE)-related dose reductions occurred in 3.6% versus 31.1% of patients; grade ≥3 treatment-emergent AEs (TEAEs) occurred in 40.0% versus 67.4% of patients; and treatment discontinuations because of TEAEs occurred in 4.3% versus 15.2% of patients, respectively. CONCLUSION: Pirtobrutinib demonstrated superiority over BendaR in IRC-assessed PFS in treatment-naïve CLL/SLL. OS trends favored pirtobrutinib despite the study design allowing for crossover. Pirtobrutinib was well tolerated, consistent with its known safety profile, and more favorable than BendaR.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jurczak W, Kwiatek M, Czyz J, et al. BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. J Clin Oncol. 2025. PMID: 41363773. doi:10.1200/JCO-25-02380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。